Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2024-03-15 00:00:00 ET · period of report 2024-03-14 · accession 0000914475-24-000096 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-15 | 2024-03-14 | NBIX | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $80.90 | +75.0K | 110.3K | +212% | +$6.07M |
| DM | 2024-03-15 | 2024-03-14 | NBIX | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $139.38 | -75.0K | 40.8K | -65% | -$10.45M |
| DM | 2024-03-15 | 2024-03-14 | NBIX | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $80.90 | -75.0K | 33.9K | -69% | -$6.07M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-14 | M | A | 5,479 | $79.02 | 46,257 | D | — | — | (F1) Includes an aggregate of 162 shares purchased on February 29, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2024-03-14 | S | D | 5,479 | $139.38 | 40,778 | D | — | — | (F3) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $137.83 to $142.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2024-03-14 | M | A | 69,521 | $81.05 | 110,299 | D | — | — | |
| 4 | Common | Common Stock | 2024-03-14 | S | D | 69,521 | $139.38 | 40,778 | D | — | — | (F3) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $137.83 to $142.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 5 | Derivative | Non-Qualified Stock Option | 2024-03-14 | M | D | 69,521 | $81.05 | 12,587 | D | $81.05 · — to 2029-02-07 | 69,521 Common Stock | (F5) The option was granted February 7, 2019 and vested in 48 equal monthly installments beginning March 7, 2019. These options will expire ten years from the date of grant on February 07, 2029. |
| 6 | Derivative | Non-Qualified Stock Option | 2024-03-14 | M | D | 5,479 | $79.02 | 33,881 | D | $79.02 · — to 2032-01-31 | 5,479 Common Stock | (F4) The option was granted January 31, 2022 and vested in 48 equal monthly installments beginning February 28, 2022. These options will expire ten years from the date of grant on January 31, 2032. |